Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
| Autor: | Livingstone, E., Gogas, H., Kandolf-Sekulovic, L., Meier, F., Eigentler, T.K., Ziemer, M., Terheyden, P.A.M., Gesierich, A.H., Herbst, R.A., Kähler, K.C., Ziogas, D.C., Mijuskovic, Z., Garzarolli, M., Garbe, C., Roesch, A., Ugurel, S., Gutzmer, R., Grob, J.J., Kiecker, F., Utikal, J., Windemuth-Kieselbach, C., Eckhardt, S., Zimmer, L., Schadendorf, D. |
|---|---|
| Zdroj: | In European Journal of Cancer September 2023 190 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect